#USA #Avid Bioservices #Tustin #Rick McAvoy #CBO Appointment

Avid Bioservices Welcomes Rich McAvoy as Chief Business Officer

On January 16, 2026, Avid Bioservices, a prominent player in the contract development and manufacturing organization (CDMO) sector, announced the appointment of Rich McAvoy as its Chief Business Officer (CBO). McAvoy brings a wealth of experience in strategic investment management, operational finance, compliance, and risk management to his new role, reinforcing Avid's commitment to scalable growth and exceptional customer care.

A New Era for Avid Bioservices

As Avid enters a significant growth phase, the company’s focus will be on enhancing operational execution and customer experiences. Kenneth Bilenberg, the CEO of Avid Bioservices, emphasized the importance of McAvoy’s extensive background in cultivating disciplined organizations that prioritize reliable delivery. “Rich is an astute leader known for aligning strategy with precise execution while maintaining discipline in prioritization, compliance, and risk management,” said Bilenberg. His leadership is expected to significantly impact Avid’s ability to strengthen its partnerships and expand its operations in an increasingly competitive biopharmaceutical landscape.

Industry Context

McAvoy's entry into the organization comes at a crucial juncture for the biopharmaceutical industry, where there is a pressing need for strategies aimed at bolstering supply chain resilience due to geopolitical uncertainties and an emphasis on U.S. manufacturing. Avid has built a reputation for quality and reliability, and McAvoy is enthusiastic about joining the team as they push toward clear growth targets. “I am looking forward to focusing on disciplined execution and ensuring we continue to deliver consistently and on time, while providing an exceptional experience to our customers,” he remarked.

Commitment to Excellence

In his role as CBO, McAvoy will play a pivotal part in linking Avid’s growth strategy with operational excellence. The anticipation surrounding his appointment reflects broader industry dynamics, with many organizations reevaluating their strategies in light of recent challenges. McAvoy intends to utilize a disciplined approach to enhance execution, distinguishing Avid from its competitors. His aim is to make Avid the preferred partner for biopharmaceutical companies through consistent delivery and active collaboration.

Avid Bioservices specializes in mammalian cell culture manufacturing and has garnered accolades for its ability to navigate complex global regulatory landscapes. The company has established a flawless record with the FDA, which speaks volumes about its rigorous quality standards and operational agility. McAvoy’s leadership is expected to bolster Avid’s preparations for supporting critical programs in both clinical and commercial supply chains.

With over 600 batches produced and more than 275 commercial batches delivered globally, Avid continues to fulfill the stringent demands of its biopharmaceutical partners. The company aims to facilitate robust growth in the coming years by embedding a culture that values reliability and meticulous execution at all levels.

As Avid Bioservices embarks on this new chapter under McAvoy’s leadership, stakeholders can anticipate enhanced partnerships and an unwavering commitment to delivering the highest quality in biopharmaceutical manufacturing processes. This strategic appointment underscores Avid’s vision of setting new standards in customer collaboration and operational excellence in the CDMO space.